Anupma Nayak, MD

DeMichele A, Clark A, Shea E, Bayne L, Sterner C, Rohn K, Eberle-Dwyer S, Pan T-C, Nivar I, Chen Y, Wileyto EP, Berry L, DeLuca S, Savage J, Makhlin I, Pant D, Egunsola A, Mears N, Goodspeed B, Chislock E, Graves J, Wang J, Shih N, Belka G, Berry D, Nayak A, Feldman M, Martin H, Chodosh L. Targeting Dormant Tumor Cells to Prevent Recurrent Breast Cancer: a randomized phase 2 trial. , Nature Medicine: 2025

Griffin B. Spychalski1, Andrew A. Lin, Stephanie J. Yang, Hanfei Shen, Jean Rosario, Kyle Tien, Kate French, Miriyam Ghali, Stephanie Yee, Melinda Yin, Michael D. Feldman, Emily F. Conant, Susan P. Weinstein, Erica L. Carpenter, David Issadore, Anupma Nayak miRNA Panel from HER2+ and CD24+ Plasma Extracellular Vesicle Subpopulations as Biomarkers of Early-stage Breast Cancer , Breast Cancer Res., 27(1): 2025,90

Narasimhamurthy M, Le A, Boruah N, Moses R, Kelly G, Bleiweiss I, Maxwell KN, Nayak A. Clinicopathologic Features of Breast Tumors in Germline TP53 Variant-Associated Li-Fraumeni Syndrome. , Am J Surg Pathol., 49(3): 2025,195-205

Kaitlin Demarest, Arravinth Anantharajah, Kara N. Maxwell1, Mersedeh Rohanizadegan, Angela Bradbury, Katherine L Nathanson, Susan Domchek, Anupma Nayak, Payal D. Shah Pathogenic Germline Variants in Patients with Metaplastic Breast Cancer , JAMA Network Open , 8(2): 2025

Young AJ, Pantel AR, Kiani M, Doot RK, Bagheri S, Pryma DA, Farwell MD, Li S, Lee H, Schubert EK, Secreto A, Zuckerman SP, Nayak A, Choi H, Carlin S, DeMichele A, Mankoff DA, Zhou R, Mach RH, McDonald ES. Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted 18F-Fluorthanatrace PET in Breast Cancer. , J Nucl Med. , 65((12)): 2024,1862-68

Tchou J, Gottipati S, Goldbach M, Baxter M, Venters S, Chen Y, Gonzalves D, Ahmad Z, Nayak A, Mukhtar R, Boughey J. Change in Biomarker Profile after neoadjuvant chemotherapy is prognostic and is especially common in patients with HER2+ breast cancer. , Ann Surg Oncol., 31(12): 2024,8093-8101

Li X, Nguyen TTA, Zhang J, Nayak A, Liu Y, Duckworth LA, Zhang G, Bakkar R, Agarwal I, Hou Y, Guo H, Huang X, Wei S, Yasmeen S, Thaer K, Huang H, Zhang H, Smith GH, Turashvili G, Peng L, Liu Y, Yang W, Siziopikou KP. Validation Study of the Newly Proposed Refined Diagnostic Criteria for Malignant Phyllodes Tumor With 136 Borderline and Malignant Phyllodes Tumor Cases , Am J Surg Pathol., 48(9): 2024,1146-1153

Ito K, Harada I, Martinez C, Sato K, Lee E, Port E, Byerly JH, Nayak A, Tripathi E, Zhu J, Irie HY. MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases. , Cancer Res Commun., 28(4): 2024,946-957

Wineland D, Le AN, Hausler R, Kelly G, Barrett E, Desai H, Wubbenhorst B, Pluta J, Bastian P, Symecko H, D'Andrea K, Doucette A, Gabriel P, Reiss KA, Nayak A, Feldman M, Domchek SM, Nathanson KL, Maxwell KN; Regeneron Genetics Center; Penn Medicine Biobank. Biallelic BRCA loss and homologous recombination deficiency in non-breast/ovarian tumors in germline BRCA1/2 carriers , JCO Precis Oncol.: 2023,e2300036

Thacker G, Henry S, Nandi A, Debnath R, Singh S, Nayak A, Susnik B, Boone MM, Zhang Q, Kesmodel SB, Gumber S, Das GM, Kambayashi T, Dos Santos CO, Chakrabarti R. Immature natural killer cells promote progression of triple-negative breast cancer. , Sci Transl Med., 15(686): 2023,eabl4414